# Innovation Corps (I-Corps) at NIH Program for NIH and CDC Translational Research (Admin Supp Clinical Trial NOT Allowed)

Source: https://welltoldgrants.com/grants/par-22-073-innovation-corps-i-corps-at-nih-program-for/  
Official notice: https://www.grants.gov/search-results-detail/336643

> National Institutes of Health offered grants to small businesses. Applications closed on February 2, 2024.

| Field | Value |
|---|---|
| Opportunity number | PAR-22-073 |
| Agency | National Institutes of Health |
| Status | Forecast |
| Deadline | February 2, 2024 |
| Award ceiling | not stated |
| Award floor | not stated |
| Expected awards | not stated |
| Total funding | not stated |
| Cost sharing | not required |
| Assistance Listings | 93.084, 93.113, 93.121, 93.172, 93.173, 93.213, 93.233, 93.242, 93.262, 93.273, 93.279, 93.307, 93.350, 93.351, 93.361, 93.393, 93.394, 93.395, 93.396, 93.397, 93.398, 93.399, 93.837, 93.838, 93.839, 93.840, 93.846, 93.847, 93.853, 93.855, 93.859, 93.865, 93.866, 93.867 |

## Who can apply

- Small businesses

Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.

## What the grant funds

Through this I-Corps at NIH program Funding Opportunity Announcement (FOA), NIH and CDC provide administrative supplement awards to active SBIR (NIH and CDC) and STTR Phase I (NIH only) grantees/awardees. The I-Corps at NIH mission is to empower entrepreneurs in developing and validating a strategic business model through diverse customer discovery in order to meet unmet clinical needs. I-Corps enables and accelerates the transformation of invention to impact SBIR and STTR Phase I awardees in a no-cost extension are eligible as long as, if selected, their no cost extension covers the entire duration of I-Corps at NIH cohort. The program provides three-member project teams with access to instruction and mentoring to accelerate the translation of technologies currently being developed with NIH and CDC SBIR and STTR funding. It is anticipated that outcomes for the I-Corps teams participating in this program will include significantly refined commercialization plans and well-informed pivots in their overall commercialization strategies. Prospective applicants are strongly encouraged to contact Scientific/Research staff for more information about the program before applying.

## Questions people ask

### Is PAR-22-073 still open?

No. It closed on February 2, 2024.

### Who can apply for Innovation Corps (I-Corps) at NIH Program for NIH and CDC Translational Research (Admin Supp Clinical Trial NOT Allowed)?

National Institutes of Health accepted applications from small businesses. The notice adds further conditions, so read its eligibility section.

### What is the deadline for Innovation Corps (I-Corps) at NIH Program for NIH and CDC Translational Research (Admin Supp Clinical Trial NOT Allowed)?

Closed February 2, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### Who has been funded under PAR-22-073?

NIH RePORTER lists 103 projects funded under PAR-22-073 in fiscal 2022 to 2024, at 102 institutions. The most were at Visionquest Biomedical Inc, Stem Pharm, Inc., Actiox LLC.

### Who has won Prevention of Disease, Disability, and Death by Infectious Diseases   grants before?

The largest recipients over five fiscal years were Puerto Rico Science, Technology, and Research Trust, Massachusetts Department of Public Health, Emory University. The program made 128 awards worth $241 million in that time.